Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer

Preclinical data support a role for the IL-6/JAK2/STAT3 signaling pathway in breast cancer. Ruxolitinib is an orally bioavailable receptor tyrosine inhibitor targeting JAK1 and JAK2. We evaluated the safety and efficacy of ruxolitinib in patients with metastatic breast cancer. This was a non-randomi...

Full description

Saved in:
Bibliographic Details
Published in:NPJ Breast Cancer
Main Authors: Stover, Daniel G., Gil Del Alcazar, Carlos R., Brock, Jane, Guo, Hao, Overmoyer, Beth, Balko, Justin, Xu, Qiong, Bardia, Aditya, Tolaney, Sara M., Gelman, Rebecca, Lloyd, Maxwell, Wang, Yu, Xu, Yaomin, Michor, Franziska, Wang, Vivian, Winer, Eric P., Polyak, Kornelia, Lin, Nancy U.
Format: Artigo
Language:Inglês
Published: Nature Publishing Group UK 2018
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5935675/
https://ncbi.nlm.nih.gov/pubmed/29761158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-018-0060-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items